3D Global Biotech Inc.
3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts profess… Read more
3D Global Biotech Inc. - Asset Resilience Ratio
3D Global Biotech Inc. (6808) has an Asset Resilience Ratio of 67.56% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how 3D Global Biotech Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down 3D Global Biotech Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$714.88 Million | 67.56% |
| Total Liquid Assets | NT$714.88 Million | 67.56% |
Asset Resilience Insights
- Very High Liquidity: 3D Global Biotech Inc. maintains exceptional liquid asset reserves at 67.56% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
3D Global Biotech Inc. Industry Peers by Asset Resilience Ratio
Compare 3D Global Biotech Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for 3D Global Biotech Inc. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for 3D Global Biotech Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 62.43% | NT$647.74 Million | NT$1.04 Billion | +17.94pp |
| 2023-12-31 | 44.49% | NT$144.20 Million | NT$324.15 Million | -7.47pp |
| 2022-12-31 | 51.96% | NT$192.90 Million | NT$371.26 Million | +1.83pp |
| 2021-12-31 | 50.13% | NT$212.80 Million | NT$424.51 Million | -5.47pp |
| 2020-12-31 | 55.60% | NT$268.30 Million | NT$482.57 Million | -1.32pp |
| 2019-12-31 | 56.92% | NT$288.10 Million | NT$506.18 Million | -- |